Evidence map›Paper›PMID 38067664›Full record

ReviewMolecules (Basel, Switzerland)2023

Research Progress on Effects of Ginsenoside Rg2 and Rh1 on Nervous System and Related Mechanisms.

Silu Liu, Weijia Chen, Yan Zhao, Ying Zong, Jianming Li, Zhongmei He

Open access · goldAbstract readReview
In one paragraph

Review in Molecules (Basel, Switzerland), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed, 1 pooled it
3.7field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 1 synthesis or guideline pooled it, 24 citations in OpenAlex.

  1. Pooled it
  2. Ginsenoside Rg2 fromMolecules (Basel, Switzerland) · 2026
    Review
  3. Article
  4. Article
  5. Article
  6. Review
  7. Review
  8. Review
  9. Article
  10. Review
  11. Review
  12. Review
  13. Article
  14. Review
  15. Frontiers in aging neuroscience · 2024
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Silu LiuCollege of Chinese Medicinal Materials, Jilin Agricultural University, Changchun 130118, China.
Weijia ChenCollege of Chinese Medicinal Materials, Jilin Agricultural University, Changchun 130118, China.
Yan ZhaoCollege of Chinese Medicinal Materials, Jilin Agricultural University, Changchun 130118, China.
Ying ZongCollege of Chinese Medicinal Materials, Jilin Agricultural University, Changchun 130118, China.
Jianming LiCollege of Chinese Medicinal Materials, Jilin Agricultural University, Changchun 130118, China.
Zhongmei HeCollege of Chinese Medicinal Materials, Jilin Agricultural University, Changchun 130118, China.
Jilin Agricultural University · CN

Funding

Jilin Province Agricultural Key Core Technology Demonstration Project - Sika Deer deep Pro-cessing and Comprehensive Utilization Technology Demonstration and Promotion 202300801-04Major Science and Technology Innovation Project of Sika Deer Industry 20220304002YY; 20220304001YY
6 · The paper itself

Abstract

Neurological-related disorders are diseases that affect the body's neurons or peripheral nerve tissue, such as Parkinson's disease (PD) and Alzheimer's disease (AD). The development of neurological disorders can cause serious harm to the quality of life and functioning of the patient. The use of traditional therapeutic agents such as dopamine-promoting drugs, anticholinergic drugs, cholinesterase inhibitors, and NMDA receptor antagonists is often accompanied by a series of side effects such as drug resistance, cardiac arrhythmia, liver function abnormalities, and blurred vision. Therefore, there is an urgent need to find a therapeutic drug with a high safety profile and few side effects. Herbal medicines are rich in active ingredients that are natural macromolecules. Ginsenoside is the main active ingredient of ginseng, which has a variety of pharmacological effects and is considered to have potential value in the treatment of human diseases. Modern pharmacological studies have shown that ginsenosides Rg2 and Rh1 have strong pharmacological activities in the nervous system, with protective effects on nerve cells, improved resistance to neuronal injury, modulation of neural activity, resistance to cerebral ischemia/reperfusion injury, improvement of brain damage after eclampsia hemorrhage, improvement of memory and cognitive deficits, treatment of AD and vascular dementia, alleviation of anxiety, pain, and inhibition of ionic-like behavior. In this article, we searched the pharmacological research literature of Rg2 and Rh1 in the field of neurological diseases, summarized the latest research progress of the two ginsenosides, and reviewed the pharmacological effects and mechanisms of Rg2 and Rh1, which provided a new way of thinking for the research of the active ingredients in ginseng anti-neurological diseases and the development of new drugs.

Indexed as

GinsenosidesPanaxHumansNervous SystemQuality of Lifeginsenoside Rg2Ginsenosidesginsenoside Rg2ginsenoside Rh1mechanism of actionnervous systempharmacological effect

Identifiers

PMID38067664
PMCPMC10708332
OpenAlexW4389304575

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.